Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot
Enanta Pharmaceuticals reported a Q4 loss of $23.7 million, or 81 cents per share, with revenue of $12.9 million. For the full year, the company had a loss of $68.2 million, or $2.35 per share, on revenue of $63 million, according to the company.
How this was made

The 30-second read
Why it matters
This is a direct earnings datapoint that can influence short-term positioning and subsequent analyst estimate updates, but it does not include guidance, pipeline updates, or balance-sheet details.
Market read
Traders can use the reported quarterly loss and revenue to reassess near-term expectations for ENTA, though the lack of guidance limits decision precision.
What to watch
The article lacks cash balance, burn rate, pipeline milestones, and any forward guidance, which are typically key for biotech valuation beyond EPS and revenue.
Background
The piece is an AP earnings snapshot generated from Zacks data, reporting Enanta’s fiscal Q4 and full-year loss and revenue figures.
Ticker impact
Enanta Pharmaceuticals reported fiscal Q4 results, posting a $23.7 million loss and $12.9 million revenue for the quarter.
Likely downward pressure as the market digests the quarterly loss and modest revenue level.
The article discloses the company’s own quarterly EPS loss and revenue, but provides no guidance or segment detail to gauge trajectory beyond the headline figures.
Market effects
Adds another data point for small-cap biotech earnings quality and cash-burn expectations, but no direct read-across catalysts are provided.
Limited, company-specific impact for US biotech investors.
Low, no international regulatory or product developments mentioned.
Counterpoint
Investors may treat the loss as expected for an early-stage biotech and focus on whether revenue trends are stabilizing, rather than the accounting loss.
Key entities
- companyEnanta Pharmaceuticals Inc.
US-listed biotech reporting fiscal Q4 loss and revenue figures.